U.S. Capital Wealth Advisors LLC Purchases 3,034 Shares of Johnson & Johnson (NYSE:JNJ)

U.S. Capital Wealth Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.7% during the third quarter, HoldingsChannel reports. The fund owned 115,054 shares of the company’s stock after buying an additional 3,034 shares during the quarter. Johnson & Johnson comprises about 1.0% of U.S. Capital Wealth Advisors LLC’s portfolio, making the stock its 14th largest holding. U.S. Capital Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $18,795,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Red Wave Investments LLC raised its stake in Johnson & Johnson by 2.0% during the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock worth $530,000 after buying an additional 59 shares during the period. Argus Investors Counsel Inc. increased its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock worth $1,941,000 after purchasing an additional 61 shares in the last quarter. Alta Capital Management LLC increased its holdings in Johnson & Johnson by 0.4% during the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock worth $2,808,000 after purchasing an additional 61 shares in the last quarter. Paces Ferry Wealth Advisors LLC increased its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after purchasing an additional 62 shares in the last quarter. Finally, Mason & Associates Inc increased its holdings in Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after purchasing an additional 62 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.74 on Monday. The stock has a fifty day simple moving average of $176.14 and a two-hundred day simple moving average of $171.20. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The firm has a market cap of $441.17 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 3.19 and a beta of 0.56. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.68%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Ashley Mcevoy sold 73,323 shares of the stock in a transaction on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the sale, the executive vice president now owns 41,813 shares in the company, valued at approximately $7,336,927.11. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock worth $40,960,735 over the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on JNJ shares. Morgan Stanley decreased their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Atlantic Securities decreased their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Sanford C. Bernstein reduced their target price on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Raymond James reduced their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Finally, Bank of America reduced their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $181.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.